



Fate Therapeutics, Inc.
Investor Relations Department
3535 General Atomics Ct.
Suite 200
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: FATE

| | |
|---------------|----------------------------|
| Last Trade: | 2.77 |
| Trade Time: | 4:00 PM ET Jul 27, 2017 |
| Change: | -0.06 (- 2.120%) |
| Day Range | 2.70 - 2.88 |
| 52-Week Range | 1.80 - 5.68 |
| Volume | 304,620 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

May 15, 2017

[Fate Therapeutics Reports First Quarter 2017 Financial Results](#)

May 10, 2017

[Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors](#)

May 8, 2017

[Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2017 Financial Results](#)

Apr 27, 2017

[Fate Therapeutics to Kick-Off 2017 Annual Meeting of International Society for Stem Cell Research with Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Focus Session](#)

Apr 20, 2017

[Fate Therapeutics to Present at the 5th Annual Cell & Gene Therapy Investor Day](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Mar 22, 2017

[Proxy Statement \(DEF 14A\)](#)

May 15, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)